They are:
- Eylea (Regeneron) — $2.58 billion
- Keytruda (Merck) — $1.81 billion
- Opdivo (Bristol Myers Squibb) — $1.72 billion
- Rituxan (Roche) — $1.70 billion
- Prolia/Xgeva (Amgen) — $1.42 billion
- Neulasta (Amgen) — $1.37 billion
- Lucentis (Genentech) — $1.22 billion
- Remicade (J&J) — $1.15 billion
- Avastin (Genentech) — $1.01 billion
- Herceptin (Genentech) — $823 million
More articles on pharmacy:
Ohio pharmacy board reverses hydroxychloroquine ban
US to pay Sanofi, GlaxoSmithKline up to $2.1B for development, 100M doses of coronavirus vaccine
25% of diabetes patients rationing treatments amid pandemic, survey finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
